ReviewPLoS pathogens2023
Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities.
Review in PLoS pathogens, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- Associations between serological evidence of SARS-CoV-2 infection and longitudinal pulmonary outcomes among people with HIV: analysis of the MACS/WIHS combined cohort study (MWCCS).Respiratory research · 2026Article
- SARS-CoV-2 infection disrupts syncytial and endothelial integrity and alters PlGF levels in the placenta.Placenta · 2025Article
- Hospitalization and Mortality in Brazilian Children and Adolescents Due to COVID-19: Retrospective Study.JMIR pediatrics and parenting · 2025Article
- COVID-19 and Parasitic Co-Infection: A Hypothetical Link to Pulmonary Vascular Disease.Infectious disease reports · 2025Review
- Three-Year Follow-Up of COVID-19 Cases in District of Constance, Germany. A Prospective, Controlled Cohort Study (FSC19-KN).Journal of clinical medicine · 2025Article
- Unraveling the enigma of long COVID: novel aspects in pathogenesis, diagnosis, and treatment protocols.Inflammopharmacology · 2024Review
- Article
- Poor nutrition doubles post-COVID-19 syndrome risk in cancer patients: insights from a Chinese multicentre study.Frontiers in nutrition · 2024Article
- CCR5/CXCR3 antagonist TAK-779 prevents diffuse alveolar damage of the lung in the murine model of the acute respiratory distress syndrome.Frontiers in pharmacology · 2024Article
- SARS-CoV-2 spread to endocrine organs is associated with obesity: an autopsy study of COVID-19 cases.Endocrine · 2024Article
- Long COVID: Molecular Mechanisms and Detection Techniques.International journal of molecular sciences · 2023Review
- Endothelial dysfunction in autoimmune, pulmonary, and kidney systems, and exercise tolerance following SARS-CoV-2 infection.Frontiers in medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 9 institutions in 6 countries.
Funding
Abstract
The Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its sublineages pose a new challenge to healthcare systems worldwide due to its ability to efficiently spread in immunized populations and its resistance to currently available therapies. COVID-19, although targeting primarily the respiratory system, is also now well established that later affects every organ in the body. Most importantly, despite the available therapy and vaccine-elicited protection, the long-term consequences of viral infection in breakthrough and asymptomatic individuals are areas of concern. In the past two years, investigators accumulated evidence on how the virus triggers our immune system and the molecular signals involved in the cross-talk between immune cells and structural cells in the pulmonary vasculature to drive pathological lung complications such as endothelial dysfunction and thrombosis. In the review, we emphasize recent updates on the pathophysiological inflammatory and immune responses associated with SARS-CoV-2 infection and their potential long-term consequences that may consequently lead to the development of pulmonary vascular diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.